Clinical Trials Browser

Has results × Prostatic Neoplasms × Etoposide × Clear all

NCT03582475 2025-11-12

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

Phase 1 Active not recruiting

15 enrolled 17 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Prostatic Neoplasms, Urethral Neoplasms

NCT00483561 2023-09-13

Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 2 Terminated

26 enrolled 7 charts

Prostatic Neoplasms

NCT00004054 2020-10-22

Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer

Phase 3 Completed

397 enrolled 11 charts

Prostatic Neoplasms

NCT00514540 2020-09-01

Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer

Phase 2 Completed

121 enrolled 8 charts

Prostatic Neoplasms

NCT01084759 2016-05-09

A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer

Phase NA Completed

16 enrolled 12 charts

Prostatic Neoplasms

NCT00176605 2014-05-20

Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer

Phase 2 Completed

15 enrolled 7 charts

Prostatic Neoplasms

NCT00028769 2013-07-16

S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer

Phase 2 Completed

41 enrolled 12 charts

Prostatic Neoplasms